Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company is engaged in the discovery, development, manufacture and marketing of branded and generic formulations as well as active pharmaceutical ingredients (APIs). Its therapeutic focus areas include dermatology, respiratory and oncology, with a presence across regulated and emerging markets worldwide.
| Type | Public company |
|---|---|
| Industry | Pharmaceuticals |
| Founder | Gracias Saldanha |
| Founded | 1977 |
| Headquarters | Mumbai, Maharashtra, India |
| Country | India |
| Listings | Bombay Stock Exchange, National Stock Exchange of India |
| Chairman & Managing Director | Glenn Saldanha |
Glenmark was founded in 1977 by Gracias Saldanha, a former executive in the Indian pharmaceutical industry. The company was named after his two sons, Glenn and Mark. Initially established as a maker of branded generics for the Indian market, it gradually expanded into research-led drug development and international generics.
The company's businesses are organised broadly into specialty and generic formulations, an active pharmaceutical ingredients (API) business, and a research arm focused on novel chemical entities and biologics. Its API business operates as a separately listed entity, Glenmark Life Sciences.
Glenmark operates manufacturing facilities in India and overseas, supplying both finished dosage forms and APIs to more than a hundred countries. Its formulations business is built around therapy areas such as dermatology, respiratory and oncology, alongside cardiovascular, diabetes and anti-infective products. The company markets a range of branded products in India and other emerging markets, while its generics business is significant in markets such as the United States.
Glenmark has positioned itself as one of the few Indian companies pursuing original drug discovery. Its R&D pipeline has historically included small molecules and biologics across inflammation, pain, oncology and respiratory disorders, with several molecules out-licensed to global partners during their development phases.
Glenmark is among the leading Indian-origin pharmaceutical companies by revenue and is regarded as one of the early Indian firms to combine large-scale generics manufacturing with novel drug discovery. Its out-licensing arrangements with multinational pharmaceutical companies have been cited as examples of Indian innovation in the global pharmaceutical value chain.